Comparison of different HER2/neu vaccines in adjuvant breast cancer trials: implications for dosing of peptide vaccines

References

• Small EJ, Sacks N, Nemunaitis J et al. Granulocyte macrophage colony-stimulating factor-secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer. Clin. Cancer Res.13(13), 3883–3891 (2007).
   PubMed Web of Science ®Google Scholar
• Avigan D, Vasir B, Gong J et al. Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responses. Clin. Cancer Res.10, 4699–4708 (2004).
   PubMed Web of Science ®Google Scholar
• Cho HI, Niu G, Bradley N, Celis E. Optimized DNA vaccines to specifically induce therapeutic CD8 T cell responses against autochtonous breast tumors. Cancer Immunol. Immunother.57, 1695–1703 (2008).
   PubMed Web of Science ®Google Scholar
• Disis ML, Gooley TA, Rinn K et al. Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines. J. Clin. Oncol.20, 2624–2632 (2002).
   PubMed Web of Science ®Google Scholar
• Slingluff CL Jr, Engelhard VH, Ferrone S. Peptide and dendritic cell vaccines. Clin. Cancer Res.12, 2342s–2345s (2006).
   Web of Science ®Google Scholar
• Celis E. Toll-like receptor ligands energize peptide vaccines through multiple paths. Cancer Res.67, 7945–7947 (2007).
   PubMed Web of Science ®Google Scholar
• Slingluff CL, Speiser DE. Progress and controversies in developing cancer vaccines. J. Transl. Med.3, 18 (2005).
   PubMed Web of Science ®Google Scholar
• Peoples GE, Holmes JP, Hueman MT et al. Combined clinical trial results of a HER2/neu (E75) vaccine for the prevention of recurrence in high-risk breast cancer patients: U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Clin. Cancer Res.14, 797–803 (2008).
   PubMed Web of Science ®Google Scholar
• Carmichael MG, Benavides LC, Holmes JP et al. Results of the first Phase 1 clinical trial of the HER-2/neu peptide (GP2) vaccine in disease-free breast cancer patients: United States Military Cancer Institute Clinical Trials Group Study I-O4. Cancer116, 292–301 (2010).
   PubMed Web of Science ®Google Scholar
• Holmes JP, Benavides LC, Gates JD et al. Results of the first Phase I clinical trial of the novel Il-key hybrid preventive HER-2/neu peptide (AE37) vaccine. J. Clin. Oncol.26, 3426–3433 (2008).
   PubMed Web of Science ®Google Scholar
• Hueman MT, Dehqanzada ZA, Novak TE et al. Phase I clinical trial of a HER-2/neu peptide (E75) vaccine for the prevention of prostate-specific antigen recurrence in high-risk prostate cancer patients. Clin. Cancer Res.11, 7470–7479 (2005).
   PubMed Web of Science ®Google Scholar
• Woll MM, Fisher CM, Ryan GB et al. Direct measurement of peptide-specific CD8+ T cells using HLA-A2:Ig dimer for monitoring the in vivo immune response to a HER2/neu vaccine in breast and prostate cancer patients. J. Clin. Immunol.24, 449–461 (2004).
   PubMed Web of Science ®Google Scholar
• Knutson KL, dela Rosa C, Disis ML. Laboratory analysis of T-cell immunity. Front. Biosci.11, 1932–1944 (2006).
   PubMed Web of Science ®Google Scholar
• Sokal JE. Editorial: measurement of delayed skin-test responses. N. Engl. J. Med.293, 501–502 (1975).
   PubMed Web of Science ®Google Scholar
• Peoples GE, Gurney JM, Hueman MT et al. Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patients. J. Clin. Oncol.23, 7536–7545 (2005).
   PubMed Web of Science ®Google Scholar
• Humphreys RE, Adams S, Koldzic G, Nedelescu B, von Hofe E, Xu M. Increasing the potency of MHC class II-presented epitopes by linking to Ii-Key peptide. Vaccine18, 2693–2697 (2000).
   PubMed Web of Science ®Google Scholar
• Adams S, Humphreys RE. Invariant chain peptides enhancing or inhibiting the presentation of antigenic peptides by major histocompatibility complex class II molecules. Eur. J. Immunol.25, 1693–1702 (1995).
   PubMed Web of Science ®Google Scholar
• Gillogly ME, Kallinteris NL, Xu M, Gulfo JV, Humphreys RE, Murray JL. Ii-Key/HER-2/neu MHC class-II antigenic epitope vaccine peptide for breast cancer. Cancer Immunol. Immunother.53, 490–496 (2004).
   PubMed Web of Science ®Google Scholar
• Kallenteris NL, Wu S, Lu X, Humphreys RE, von Hofe E, Xu M. Enhanced CD4+ T-cell response in DR4-transgenic mice to a hybrid peptide linking the Ii-key segment of the invariant chain to the melanoma gp100(48–58) MHC class II epitope. J. Immunother.28, 352–358 (2005).
   PubMed Web of Science ®Google Scholar
• Lee TD. Distribution of HLA antigens in North American Caucasians, North American Blacks and Orientals. In: The HLA System. Lee J (Ed.). Springer-Verlag, NY, USA, 141 (1990).
   Google Scholar
• Parker KC, Bednarek MA, Coligan JE. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J. Immunol.152, 163–175 (1994).
   PubMed Web of Science ®Google Scholar
• Rammensee HG, Bachmann J, Stevanovic S. MHC Ligands and Peptide Motifs. Landes Bioscience, NY, USA (1997).
   Google Scholar
• Mittendorf EA, Gurney JM, Storrer CE, Shriver CD, Ponniah S, Peoples GE. Vaccination with a HER2/neu peptide induces intra- and inter-antigenic epitope spreading in patients with early stage breast cancer. Surgery139, 407–418 (2006).
   PubMed Web of Science ®Google Scholar
• Brossart P, Wirths S, Stuhler G, Reichardt VL, Kanz L, Brugger W. Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood96, 3102–3108 (2000).
   PubMed Web of Science ®Google Scholar
• Disis ML, Schiffman K, Gooley TA, McNeel DG, Rinn K, Knutson KL. Delayed-type hypersensitivity response is a predictor of peripheral blood T-cell immunity after HER-2/neu peptide immunization. Clin. Cancer Res.6, 1347–1350 (2000).
   PubMed Web of Science ®Google Scholar
• Wolff AC, Hammond ME, Schwartz JN et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J. Clin. Oncol.25, 118–145 (2007).
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Godolphin W, Jones LA et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science244, 707–712 (1989).
   PubMed Web of Science ®Google Scholar
• Benavides LC, Gates JD, Carmichael MG et al. The impact of HER2/neu expression level on response to the E75 vaccine: From U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Clin. Cancer Res.15, 2895–2904 (2009).
   PubMed Web of Science ®Google Scholar
• Holmes JP, Gates JD, Benavides LC et al. Optimal dose and schedule of an HER-2/neu (E75) peptide vaccine to prevent breast cancer recurrence: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Cancer113, 1666–1675 (2008).
   PubMed Web of Science ®Google Scholar